Predictive validity of the simplified Radiographic Assessment of Lung Edema score for
 the mortality in critically ill COVID-19 patients with the B.1.617.2 (Delta) variant in
 Vietnam: a single-centre, cross-sectional study

Son Ngoc Do^{1,2,3}, Tuan Quoc Dang^{1,2}, Chinh Quoc Luong^{2,3,4}, My Ha Nguyen⁵, Dung Thi 4 Pham⁶, Viet Khoi Nguyen^{7,8}, Tan Dang Do⁷, Thai Quoc Nguyen⁹, Vuong Minh Nong⁹, Khoi 5 Hong Vo^{10,11,12}, Tan Cong Nguyen^{1,2,3}, Nhung Hong Khuat^{2,13}, Quynh Thi Pham^{2,14}, Dat Tien 6 Hoang^{1,2}, Anh Diep Nguyen^{2,15}, Phuong Minh Nguyen^{2,16}, Duong Dai Cao^{2,17}, Dung Thuy 7 Pham^{2,18}, Dung Tuan Dang⁴, Dat Tuan Nguyen^{2,3,4}, Vinh Duc Nguyen⁴, Thuan Quang Le^{2,3,19}, 8 9 Hung Duc Ngo^{2,4}, Dung Van Nguyen⁹, Thach The Pham^{1,2,3}, Dung Tien Nguyen^{2,19}, Nguyen Trung Nguyen^{2,3,19}, Nhung Thi Huynh²⁰, Nga Thu Phan⁵, Cuong Duy Nguyen²¹, Thom Thi 10 Vu²², Cuong Duv Do^{9,23}, Chi Van Nguyen^{2,4}, Giap Van Vu^{24,25}, Co Xuan Dao^{1,2,3*} 11 ¹ Center for Critical Care Medicine, Bach Mai Hospital, Hanoi, Vietnam 12 ² Department of Emergency and Critical Care Medicine, Hanoi Medical University, Hanoi, 13 Vietnam 14 ³ Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of 15 Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam 16 ⁴ Center for Emergency Medicine, Bach Mai Hospital, Hanoi, Vietnam 17 ⁵ Department of Health Organization and Management, Faculty of Public Health, Thai Binh 18 University of Medicine and Pharmacy, Thai Binh, Vietnam 19 ⁶ Department of Nutrition and Food Safety, Faculty of Public Health, Thai Binh University of 20 Medicine and Pharmacy, Thai Binh, Vietnam 21 22 ⁷ Radiology Centre, Bach Mai Hospital, Hanoi, Vietnam ⁸ Department of Radiology, Hanoi Medical University, Hanoi, Vietnam 23 ⁹ Center for Tropical Diseases, Bach Mai Hospital, Hanoi, Vietnam 24

- ¹⁰ Department of Neuro Intensive Care and Emergency Neurology, Neurology Center, Bach
- 26 Mai Hospital, Hanoi, Vietnam
- 27 ¹¹ Department of Neurology, Hanoi Medical University, Hanoi, Vietnam
- ¹² Department of Neurology, Faculty of Medicine, University of Medicine and Pharmacy,
- 29 Vietnam National University, Hanoi, Vietnam
- 30 ¹³ Department of Intensive Care and Poison Control, Duc Giang General Hospital, Hanoi,
- 31 Vietnam
- ¹⁴ Intensive Care Unit, University Medical Center Ho Chi Minh City, University of Medicine
- and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
- ¹⁵ Intensive Care Unit, Hanoi Heart Hospital, Hanoi, Vietnam
- ¹⁶ Intensive Care Unit, Thanh Nhan General Hospital, Hanoi, Vietnam
- ¹⁷ Department of Intensive Care and Poison Control, Ha Dong General Hospital, Hanoi,
- 37 Vietnam
- ¹⁸ Stroke Center, Bach Mai Hospital, Hanoi, Vietnam
- ¹⁹ Poison Control Center, Bach Mai Hospital, Hanoi, Vietnam
- 40 ²⁰ Department of Internal Medicine, Faculty of Medicine, University of Medicine and
- 41 Pharmacy, Vietnam National University, Hanoi, Vietnam
- 42 ²¹ Department of Emergency and Critical Care Medicine, Thai Binh University of Medicine
- 43 and Pharmacy, Thai Binh, Vietnam
- ²² Department of Basic Medical Sciences, University of Medicine and Pharmacy, Vietnam
- 45 National University, Hanoi, Vietnam
- 46 ²³ Department of Infectious Diseases, Faculty of Medicine, University of Medicine and
- 47 Pharmacy, Vietnam National University, Hanoi, Vietnam
- 48 ²⁴ Respiratory Center, Bach Mai Hospital, Hanoi, Vietnam
- 49 ²⁵ Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam

50	*Corresponding	author:
----	----------------	---------

- 51 Co Xuan Dao, MD, PhD
- 52 Center for Critical Care Medicine, Bach Mai Hospital, No. 78, Giai Phong Road, Dong Da
- 53 District, Hanoi 100000, Vietnam
- 54 Email: <u>daoxuanco@gmail.com</u>
- 55 Phone number: +84.93.713.8868
- 56 ORCID: <u>https://orcid.org/0000-0002-3182-2993</u>
- 57
- 58 **Running Head**: Simplified Radiographic Assessment of Lung Edema score for predicting
- 59 mortality in critically ill COVID-19 patients in Vietnam
- 60 Article Type: Research / Original Paper
- 61 Word Count:
- 62 Abstract: 360 words
- Formal scientific presentations: 5487 words and 60 references, plus a structured abstract
- 64 **Figure/Table**: 5
- 65
- 66
- 67
- 68
- 69

70

71 ABSTRACT

72 Background

Evaluating the prognosis of COVID-19 patients who may be at risk of mortality using the
simple chest X-ray (CXR) severity scoring systems provides valuable insights for treatment
decisions. This study aimed to assess how well the simplified Radiographic Assessment of
Lung Edema (RALE) score could predict the death of critically ill COVID-19 patients in
Vietnam.

78 Methods

From July 30 to October 15, 2021, we conducted a cross-sectional study on critically ill 79 COVID-19 adult patients at an intensive care centre in Vietnam. We calculated the areas 80 under the receiver operator characteristic (ROC) curve (AUROC) to determine how well the 81 82 simplified RALE score could predict hospital mortality. In a frontal CXR, the simplified RALE score assigns a score to each lung, ranging from 0 to 4. The overall severity score is 83 84 the sum of points from both lungs, with a maximum possible score of 8. We also utilized 85 ROC curve analysis to find the best cut-off value for this score. Finally, we utilized logistic regression to identify the association of simplified RALE score with hospital mortality. 86

87 **Results**

Of 105 patients, 40.0% were men, the median age was 61.0 years (Q1-Q3: 52.0-71.0), and 79.0% of patients died in the hospital. Most patients exhibited bilateral lung opacities on their admission CXRs (99.0%; 100/102), with the highest occurrence of opacity distribution spanning three (18.3%; 19/104) to four quadrants of the lungs (74.0%; 77/104) and a high median simplified RALE score of 8.0 (Q1-Q3: 6.0-8.0). The simplified RALE score (AUROC: 0.747 [95% CI: 0.617-0.877]; cut-off value ≥5.5; sensitivity: 93.9%; specificity: 94 45.5%; P_{AUROC} <0.001) demonstrated a good discriminatory ability in predicting hospital 95 mortality. After adjusting for confounding factors such as age, gender, Charlson Comorbidity 96 Index, serum interleukin-6 level upon admission, and admission severity scoring systems, the 97 simplified RALE score of \geq 5.5 (adjusted OR: 18.437; 95% CI: 3.215-105.741; p =0.001) was 98 independently associated with an increased risk of hospital mortality.

99 Conclusions

100 This study focused on a highly selected cohort of critically ill COVID-19 patients with a high 101 simplified RALE score and a high mortality rate. Beyond its good discriminatory ability in 102 predicting hospital mortality, the simplified RALE score also emerged as an independent 103 predictor of hospital mortality.

Keywords: Acute Respiratory Distress Syndrome, Brixia scoring system, Chest X-ray,
Consolidation, COVID-19, COVID-19 pandemic, CXR severity score, Ground-glass
opacities, Intensive care unit, Reticular interstitial thickening, Lung involvement, Mortality,
Pulmonary infection, RALE scoring system, SARS-CoV-2, Total severity score.

108

109

110

- 111
- 112

113

114

115 INTRODUCTION

Since the first reports of coronavirus disease 2019 (COVID-19) cases from Wuhan, a city in 116 117 the Hubei Province of China, at the end of 2019, cases have emerged across all continents.(1-3) As of February 4, 2024, there have been more than 770 million confirmed cases of 118 COVID-19 worldwide.(4) However, the reported case counts underestimate the overall 119 burden of COVID-19, as only a fraction of acute infections are diagnosed and reported. 120 During the COVID-19 pandemic, most countries lack sufficient diagnostic tools due to the 121 rising daily number of reported cases. Therefore, it becomes crucial to correctly categorize 122 COVID-19 patients based on the severity of their symptoms for efficient resource 123 distribution.(5) Specifically, the value of oxygen saturation in the peripheral blood (SpO_2) is 124 one of the first measures checked for each patient on admission; it often reflects the degree of 125 lung function impairment. The requirement to transfer patients with COVID-19 to an 126 intensive care unit (ICU) depends mainly on their SpO₂ and concurrent comorbidities.(6) 127 Some experts have suggested that imaging can help determine this need. 128

A chest X-ray (CXR) has been suggested as a tool to predict the severity of COVID-19 by 129 130 assessing lung involvement and offering insights into the prognosis of the COVID-19 infection. A previous study introduced the CXR scoring system for quantifying the severity 131 and progression of lung abnormalities in COVID-19 pneumonia.(7) This system evaluated 132 133 the extent of COVID-19 pulmonary abnormalities on CXR using a semiquantitative severity score ranging from 0 to 3, with 1-point increments, across six lung zones (total range 0–18), 134 correlated these findings with clinical data, and assessed interobserver agreement. 135 136 Interestingly, the study revealed a moderate to almost perfect interobserver agreement and identified significant but weak correlations with clinical parameters.(7) As a result, 137 integration of CXR into the classification of COVID-19 patients is a potential avenue for 138

further exploration. Another previous study introduced a CXR scoring system called the Brixia score.(8) This score is a valuable tool for assessing the severity of COVID-19 infection. By evaluating the extent and characteristics of lung abnormalities, the Brixia score offers insights into pulmonary involvement using an 18-point severity scale.(8) While CXR is considered not sensitive in detecting early-stage pulmonary involvement, the Brixia score remains a useful diagnostic tool for identifying the rapid progression of lung abnormalities in COVID-19 patients, particularly in ICUs.(8)

To further understand the radiographic features of COVID-19, a retrospective study examines 146 the progression and severity of CXR findings associated with the disease.(9) Additionally, 147 this study adapts and simplifies the original Radiographic Assessment of Lung Edema 148 (original RALE)(10) score to quantify the extent of infection and calculate a severity score 149 for COVID-19. While 20% of patients did not exhibit any abnormalities on their CXR 150 throughout the illness, this study reveals that common abnormal CXR findings included 151 152 consolidation and ground-glass opacities.(9) These abnormalities were distributed bilaterally, peripherally, and in the lower lung zones. The CXR severity score progressively intensified 153 during the illness, reaching its peak severity between 10 to 12 days after the onset of 154 symptoms.(9) Although this study reveals that baseline CXR sensitivity is lower than those of 155 real-time reverse transcription-polymerase chain reaction (RT-PCR) tests and computed 156 tomography (CT) scans, it still suggests that CXR have a role in the initial screening for 157 COVID-19 and identifying the rapid progression of lung abnormalities in COVID-19 158 patients.(9) 159

160 Two recent published studies also show that the adaptation and simplification of the original 161 RALE score proved valuable in predicting the mortality of critically ill patients with COVID-162 19.(11, 12) However, limited data on this simplified score's external validity are available. 163 Therefore, the present study aimed to assess how well the simplified RALE score could164 predict the death of critically ill patients with COVID-19 in Vietnam.

165

166 **METHODS**

167 Study design and setting

From July 30 to October 15, 2021, we conducted a cross-sectional study on critically ill COVID-19 patients with the Delta variant at the Intensive Care Centre for the Treatment of Critically Ill Patients with COVID-19 (study centre) in Ho Chi Minh City (HCMC), Vietnam. This centre was a field hospital with 360 beds and was affiliated with the Bach Mai Hospital (BMH) in Hanoi, Vietnam. BMH is designated as the central hospital in northern Vietnam by the Ministry of Health (MOH) of Vietnam.(13) It is a large general hospital with 3,200 beds.

174 In July 2021, HCMC faced a severe Delta variant COVID-19 outbreak, which led to a high demand for ICUs for critically ill patients.(14, 15) In response, the MOH established four 175 specialized Intensive Care Centres for the Treatment of Critically Ill Patients with COVID-19 176 on July 30, 2021, which could only receive patients transferred from lower-level hospitals in 177 HCMC. The study centre was under the management of BMH and was called Field Hospital 178 Number 16. The study centre had a capacity of 500 beds at its peak and later reduced it to 179 360. The study centre stopped operating on April 30, 2022, after the COVID-19 cases 180 declined. The Director of BMH also served as the Director of the study centre. Likewise, two 181 Deputy Directors of the study centre were from the Centre for Emergency Medicine of BMH 182 in Hanoi and the Director Board of Hung Vuong Hospital in HCMC. The study centre had 183 968 medical staff and volunteers in total, and more than half of them (542 medical staff) were 184 from BMH. They came from different departments and centres of BMH, such as Emergency, 185

Intensive Care, Tropical Diseases, Respiratory, Clinical Nutrition, Nephro-Urology and
Dialysis, Neurology, Cardiovascular, Infection Control, Haematology and Blood Transfusion,
Radiology, Biochemistry, and Microbiology.

189 Participants

This study included patients aged 18 years or older who were critically ill with COVID-19 and presented to the study centre. We defined a case of COVID-19 as a person with laboratory confirmation of COVID-19 infection, regardless of clinical or epidemiological criteria.(16, 17) Laboratory confirmation of COVID-19 infection was based on a positive RT-PCR test using samples obtained from the respiratory tract by nasopharyngeal swab, throat or mouth swab, or tracheal lavage fluid.(18) We excluded patients who did not have CXRs between hospital admission and the end of the first day.

Data collection

The data for each study patient were recorded from the same unified case record forms
(CRFs). Data was entered into the study database by the online password-protected CRF.
Patient identifiers were not entered in the database to protect patients' confidentiality.

201 Variables

The CRF contained four sections, which included variables mainly based on the COVID-19 Treatment Guidelines of the National Institutes of Health(19) and collected by fully trained clinicians, such as information on:

(i) The first section focused on baseline characteristics, such as: prehospital care (e.g., prior
 hospitalization, prehospital airway, prehospital oxygen), demographics (i.e., age and gender),
 documented comorbidities (e.g., cerebrovascular disease, chronic cardiac failure, coronary

artery disease/myocardial infarction, hypertension, chronic obstructive pulmonary disease/asthma, other chronic pulmonary disease, tuberculosis, chronic renal failure, and diabetes mellitus), and details of admission. We also used the 19 comorbidity categories to compute the Charlson Comorbidity Index (CCI) Score, which measures the predicted mortality rate based on the presence of comorbidities.(20) A score of zero indicates that no comorbidities were detected; the higher the score, the higher the expected mortality rate is.(20-22)

(ii) The second section comprised characteristics upon admission, such as vital signs (e.g., 215 216 heart rate, respiration rate, arterial blood pressure, and body temperature), laboratory parameters (e.g., interleukin-6 (IL-6)), chest X-ray (CXR) findings (e.g., bilateral opacities, 217 number of involved quadrants, and severity of COVID-19 based on lung involvement), gas 218 exchange (e.g., the partial pressure of oxygen (PaO₂) and carbon dioxide (PaCO₂) in the 219 arterial blood, the acidity of the blood (pH), and the ratio of partial pressure of oxygen in 220 221 arterial blood to the fraction of inspiratory oxygen concentration (PaO₂/FiO₂)), and severity scoring systems (e.g., Sequential Organ Failure Assessment (SOFA) score(23), Acute 222 Physiology and Chronic Health Evaluation II (APACHE II) score(24), and Confusion, Urea 223 >7 mmol/L, Respiratory Rate \geq 30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 224 mm Hg (Diastolic), Age \geq 65 Years (CURB-65) score(25)). Serum IL-6 was measured using 225 the Elecsys IL-6 immunoassay (Roche[®] Cobas E411 analyser), an in vitro diagnostic test for 226 quantitatively determining IL-6 in human serum and plasma. The measuring range is from 227 1.5 - 5000pg/mL. Data on the IL-6 levels were collected prospectively on a CRF from 228 hospital admission until the end of the first day. In the present study, we defined the IL-6 229 level as 5000pg/mL when values were above the measuring range (>5000pg/mL). 230 Prospectively, we collected all necessary data elements for calculating the SOFA score, 231 APACHE II score, and CURB-65 score within the time window from admission until 24 232

hours later, entered these data into an online CRF, and stored them in a database for the 233 subsequent analysis. The CXRs were performed for severely and critically ill patients with 234 COVID-19 in a single frontal projection with an anteroposterior view by using a compact and 235 portable X-ray device (FDR nano, Model/Serial: DR-XD 1000, Fujifilm Techno Products 236 Co., Ltd) conveniently brought to the patient's bedside in the hospital or emergency room. 237 The X-ray tube was connected to a flexible arm, allowing the technician to position it over 238 the patient and place an X-ray film holder or image recording plate underneath. In 239 hospitalized patients with COVID-19, we performed a portable CRX as the initial evaluation 240 241 for pulmonary complications and lung involvement. Chest computed tomography (CT) scans were reserved for specific situations that might change clinical management, partly to 242 minimize infection control issues related to transport. These practices align with the 243 recommendations from the American College of Radiology(26). The evaluation of CXR 244 findings, which were taken from hospital admission until the end of the first day and included 245 bilateral opacities, the extent of lung involvement across quadrants, and the severity of 246 COVID-19 based on lung assessments, was a two-step process. Initially, a radiology resident 247 in their third year reviewed the CXRs. Following this, a thoracic radiologist with ten years of 248 experience independently validated the findings. Both professionals were unaware of other 249 clinical variables and outcomes. In case of any discrepancies identified in the images, they 250 collaborated to reach a consensus. We adapted and simplified the original RALE score(10) to 251 252 create a simplified RALE score for assessing the severity of COVID-19 based on lung involvement. This approach has also been used in prior published studies to quantify the 253 extent of pulmonary infection in COVID-19 cases.(9, 11, 12, 17) In a frontal CXR, the 254 simplified RALE scoring system assigns a score to each lung, ranging from 0 to 4. This score 255 reflects the attendance of specific abnormalities. The system divides each lung into four 256 zones, and abnormalities such as consolidation, ground-glass opacification, and reticular 257

interstitial thickening are assigned a score of 1 in each zone (S1 Fig in S1 File). A score of 0 258 indicates no involvement, while a score of 1 corresponds to less than 25% involvement, a 259 score of 2 represents 25% to less than 50% involvement, a score of 3 signifies 50% to less 260 than 75% involvement, and a score of 4 indicates 75% or greater involvement. The overall 261 severity score is the sum of points from both lungs, with a maximum possible score of 8. 262 Based on the simplified RALE score upon admission, the patients were classified into three 263 264 severity groups as follows: mild (a score of 1 to 2), moderate (a score of 3 to 6), and severe (a score of 7 to 8). 265

(iii) The third section captured life-sustaining treatments provided during the ICU stay, such
as respiratory support on the first day of admission (e.g., oxygen supplements and mechanical
ventilation) and adjunctive therapies (e.g., prone positioning, recruitment maneuvers,
extracorporeal membrane oxygenation, antiviral drugs, antibiotics, corticosteroids, heparin,
antiplatelet drugs, novel oral anticoagulants, recombinant humanized anti-IL-6 receptor
monoclonal antibody, continuous sedation, continuous neuromuscular blocking agents, renal
replacement therapy, cytokine adsorption therapy, tracheostomy, and inhaled vasodilators).

273 (iv) The fourth section is concerned with complications (e.g., hospital-acquired pneumonia (HAP), hypoxemic respiratory failure/ARDS, diffuse alveolar damage, secondary bacterial 274 infections, sepsis and septic shock, cardiac injury, arrhythmia, acute kidney injury, liver 275 dysfunction, multi-organ failure, thromboembolism, gastrointestinal bleeding, 276 and pneumothorax/pneumomediastinum) and clinical outcomes (e.g., hospital mortality). HAP is 277 defined as pneumonia that occurs 48 hours or more after admission and does not appear to be 278 279 incubating at the time of admission.(27) To diagnose and classify ARDS, we applied the Berlin criteria, which categorize ARDS severity based on the PaO₂/FiO₂ ratio as follows: 280 mild ($200 < PaO_2/FiO_2 \le 300 \text{ mmHg}$), moderate ($100 < PaO_2/FiO_2 \le 200 \text{ mmHg}$), and severe 281

 $(PaO_2/FiO_2 \le 100 \text{ mmHg})$, with a minimum positive end-expiratory pressure (PEEP) of 5 282 cmH₂O applied to the lungs at the end of each breath.(28, 29). Additionally, septic shock is 283 identified as a clinical construct of sepsis characterized by persisting hypotension requiring 284 vasopressors to maintain a mean arterial pressure > 65 mmHg, along with a serum lactate 285 level > 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.(30) Lastly, 286 thromboembolism encompasses venous thromboembolism (i.e., deep vein thrombosis and 287 288 pulmonary embolism), arterial events (i.e., stroke, limb ischemia, and myocardial infarction), and microvascular thrombosis (e.g., microvascular thrombosis in the lungs).(19) 289

We followed all patients till hospital discharge or death in the ICU/hospital, whichever was earliest.

292 Outcome measures

The primary outcome was hospital mortality, which we defined as death from any cause during the hospitalization. We also examined the secondary outcomes, such as complications (e.g., ARDS) and hospital lengths of stay.

296 Sample size

In this cross-sectional study, the primary outcome was hospital mortality. Therefore, we used the formula to find the minimum sample size for estimating a population proportion with a confidence level of 90%, a confidence interval (margin of error) of $\pm 8.02\%$, and an assumed population proportion of 54.64%, based on the hospital mortality (54.64%) reported in a previously published study(31). As a result, our sample size should be at least 105 patients, which might be large enough to reflect a normal distribution.

303
$$n = \frac{z^2 x \, \hat{p}(1-\hat{p})}{\varepsilon^2}$$

304 where:

- *z* is the *z* score (*z* score for a 90% confidence level is 1.65)
- 306 ε is the margin of error (ε for a confidence interval of \pm 8.02% is 0.0802)
- 307 \hat{p} is the population proportion (\hat{p} for a population proportion of 54.64% is 0.5464)
- 308 *n* is the sample size

309 Statistical analyses

We used IBM[®] SPSS[®] Statistics 22.0 (IBM Corp., Armonk, United States of America) and 310 Analyse-it statistical software (Analyse-it Software, Ltd., Leeds, United Kingdom) for data 311 analysis. We report the data as numbers (no.) and percentages (%) for categorical variables 312 and medians and interquartile ranges (Q1-Q3) or means and standard deviations (SDs) for 313 continuous variables. Furthermore, comparisons were made between survival and death in the 314 hospital for each variable using the Chi-squared or Fisher's exact test for categorical 315 316 variables and the Mann–Whitney U test, Kruskal–Wallis test, or one-way analysis of variance for continuous variables. 317

To evaluate how well the simplified RALE score, CCI score, admission serum IL-6 level, 318 SOFA score, APACHE II score, and CURB-65 score could differentiate between patients 319 who survived and those who died in the hospital, we plotted receiver operator characteristic 320 321 (ROC) curves and calculated areas under the ROC curve (AUROCs) for each score or level. We also used the ROC curve analysis to determine the best cut-off value for each score or 322 level, which was the point that gave the highest Youden's index (i.e., sensitivity + specificity 323 - 1). Then, we divided the patients into two groups based on their score or level: one that was 324 less than the cut-off or another greater than or equal to the cut-off value. Additionally, we 325 compared the AUROCs of simplified RALE score with those of the serum IL-6 level, CCI 326 score, SOFA score, APACHE II score, and CURB-65 score to see which one was better at 327

328 predicting deaths in the hospital using the Z-statistics. Finally, we calculated correlation 329 coefficients (Rs) using Spearman's rho to explore the relationship between simplified RALE 330 score and each score or level.

We assessed the association of simplified RALE Score with hospital mortality using logistic 331 regression analysis. To reduce the number of predictors and the multicollinearity issue and 332 resolve the overfitting, we used different methods to select variables as follows: (a) we put all 333 variables of demographics, documented comorbidities, clinical characteristics, CXR findings, 334 laboratory investigations, gas exchange, severity scoring systems, first-day respiratory 335 support, adjunctive therapies, complications into the univariable logistic regression model; 336 (b) we selected variables if the P-value was < 0.05 in the univariable analysis between death 337 and survival in the hospital, as well as those that are clinically crucial, to put in the 338 multivariable logistic regression model. These variables included demographics (i.e., age \geq 339 60 years, gender (male)), documented comorbidities (i.e., CCI score ≥cut-off value), CXR 340 findings (i.e., simplified RALE Score ≥cut-off value), laboratory investigations (i.e., 341 admission serum IL-6 level \geq cut-off value), severity scoring systems (i.e., SOFA score \geq cut-342 off value, CURB-65 score ≥cut-off value). Using a stepwise backward elimination method, 343 we started with the full multivariable logistic regression model that included the selected 344 variables. This method then deleted the least statistically significant variables stepwise from 345 the full model until all remaining variables were independently associated with hospital 346 mortality in the final model. We presented the odds ratios (ORs) and 95% confidence 347 intervals (CIs) in the univariable logistic regression model and the adjusted ORs (AORs) and 348 349 95% CIs in the multivariable logistic regression model.

The significance levels were two-tailed for all analyses, and we considered the P <0.05 as a statistically significant value.

352 Ethical issues

This study was approved by the Scientific and Ethics Committees of Bach Mai Hospital 353 354 (Approval number: 3412/QD-BM) and conducted according to the principles of the Declaration of Helsinki. The Bach Mai Hospital Scientific and Ethics Committees waived the 355 written informed consent for this non-interventional study. Verbal informed consents were 356 directly obtained from patients or, when unavailable, from family members over the phone or 357 at the Intensive Care Centre for the Treatment of Critically Ill Patients with COVID-19 and 358 witnessed by the on-duty medical staff. Public notification of this study was made by 359 published posting, according to the Strengthening the Reporting of Observational Studies in 360 Epidemiology (STROBE): Explanation and Elaboration - the STROBE Statement - Checklist 361 of items that should be included in reports of cross-sectional studies. The authors who 362 performed the data analysis kept the data set in password-protected systems and only 363 presented anonymized data. 364

365

366 **RESULTS**

367 **Baseline characteristics and clinical outcomes**

Of 105 patients, 40.0% were men, and the median age was 61.0 years (Q1-Q3: 52.0-71.0) (Table 1). Upon admission, nearly all patients (99.0%; 100/102) exhibited bilateral lung opacities on their CXR (Table 2). These opacities were most frequently distributed across three (18.3%; 19/104) and four quadrants of lungs (74.0%; 77/104). Additionally, the patients had a high median simplified RALE score of 8.0 (Q1-Q3: 6.0-8.0) (Table 2) and a low mean PaO₂/FiO₂ ratio of 101.66 (SD: 58.20) (Table 2). Elevated mean serum IL-6 level was observed upon admission (99.76pg/mL; SD: 174.33) (Table 2). The median SOFA score was 4.0 (Q1-Q3: 2.0-5.0), median APACHE II score was 8.0 (Q1-Q3: 3.0-12.0), and median CURB-65 score was 1.0 (Q1-Q3: 1.0-2.0) within the time window from admission until 24 hours later (Table 2). In general, 79.0% (83/105) of the patients died in the hospital (Tables 1 and 2). As shown in Tables 1 and 2 and S1 to S5 Tables (S1 File), we also compared the factors between survivors and non-survivors in the hospital, such as prehospital care, demographics, comorbidities, vital signs, laboratory investigations, CXR findings, severity scoring systems, treatments, and complications.

395	Table 1. Baseline characteristics of critical	/ ill COVID-19 patients with the	Delta variant, according to hospital survivability

Variables	All cases	Survived	Died	P value ^a	
	n=105	n=22	n=83		
Demographics					
Age (year), median (Q1-Q3)	61.0 (52.0-71.0)	53.5 (48.5-62.0)	62.0 (54.0-73.0)	0.009	
Gender (male), no. (%)	42 (40.0)	6 (27.3)	36 (43.4)	0.171	
Comorbidities					
Cerebrovascular disease, no. (%), n=78	5 (6.4)	0 (0.0)	5 (7.7)	0.583	
Chronic cardiac failure, no. (%), n=78	4 (5.1)	2 (15.4)	2 (3.1)	0.127	
Coronary artery disease/MI, no. (%), n=78	4 (5.1)	1 (7.7)	3 (4.6)	0.525	
Hypertension, no. (%), n=78	50 (64.1)	7 (53.8)	43 (66.2)	0.528	
COPD/asthma, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999	
Other chronic pulmonary disease, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999	
Tuberculosis, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999	
Chronic renal failure, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999	
Diabetes mellitus, no. (%), n=78	40 (51.3)	5 (38.5)	35 (53.8)	0.311	
CCI score, median (Q1-Q3), n=102	2.0 (1.0-4.0)	1.0 (0.0-2.5)	2.0 (1.0-4.0)	0.023	
Vital signs upon admission					
HR (beats/min), median (Q1-Q3), n=99	92.0 (80.0-100.0)	90.0 (84.75-100.75)	95.0 (80.0-100.0)	0.871	
RR (breaths/min), median (Q1-Q3), n=97	26.0 (25.0-30.0)	25.0 (22.0-27.0)	28.0 (25.0-31.5)	0.006	

Systolic BP (mmHg), mean (SD), n=99	124.97 (17.58)	127.59 (15.03)	124.22 (18.27)	0.573
Diastolic BP (mmHg), mean (SD), n=98	75.91 (11.51)	79.0 (8.40)	75.06 (12.13)	0.195
Body temperature (°C), mean (SD), n=95	36.95 (0.37)	36.94 (0.15)	36.95 (0.41)	0.390

^a The comparison between patients who survived and those who died in the hospital.

<u>Abbreviations</u>: **BP**, blood pressure; **CCI**, Charlson Comorbidity Index; **COPD**, chronic obstructive pulmonary disease; **HR**, heart rate; **MI**, myocardial infarction; **no.**, number of patients; **Q**, quartile; **RR**, respiration rate; **SD**, standard deviation.

- 397 Table 2. Laboratory investigations, gas exchange, chest X-ray findings, and severity scoring systems of critically ill COVID-19 patients with the
- 398 Delta variant upon admission, according to hospital survivability

Variables	All cases	Survived	Died	P value ^a
	n=105	n=22	n=83	
Laboratory investigations				
WBC (G/L), mean (SD)	12.94 (5.73)	11.94 (4.78)	13.21 (5.95)	0.587
Hemoglobin (g/dL), mean (SD)	123.79 (25.81)	118.97 (29.59)	125.06 (24.75)	0.317
Platelet count (G/L), mean (SD)	270.15 (187.08)	310.5 (330.35)	259.46 (126.04)	0.937
CRP (mg/L), mean (SD), n=90	10.85 (10.85)	13.96 (26.87)	9.96 (4.99)	0.295
Glucose (mmol/L), mean (SD), n=101	11.60 (6.30)	11.98 (9.46)	11.52 (5.39)	0.473
Ure (mmol/L), mean (SD), n=104	8.56 (6.92)	6.9 (6.81)	9.01 (6.92)	0.005
Creatinine (µmol/L), mean (SD), n=104	89.79 (47.51)	79.59 (38.51)	92.52 (49.49)	0.040
INR, mean (SD)	3.52 (16.65)	5.76 (20.83)	2.92 (15.46)	0.576
Interleukin 6 (pg/mL), mean (SD), n=90	99.76 (174.33)	66.68 (85.36)	109.83 (192.86)	0.128

³⁹⁶

Gas exchange				
pH, mean (SD), n=63	7.41 (0.11)	7.48 (0.05)	7.39 (0.11)	0.006
PaO ₂ (mmHg), mean (SD), n=63	80.98 (48.85)	84.18 (27.03)	80.31 (52.49)	0.135
PaO ₂ /FiO ₂ ratio, mean (SD), n=62	101.66 (58.20)	126.74 (57.98)	96.26 (57.38)	0.045
SpO ₂ (%), mean (SD), n=87	92.54 (5.29)	94.38 (4.26)	92.13 (5.44)	0.042
Chest X-ray findings				
Bilateral opacities, no. (%), n=102	100 (99.0)	19 (95.0)	82 (100.0)	0.196
Number of involved quadrants, n=104				< 0.001
1 quadrant, no. (%)	1 (1.0)	1 (4.8)	0 (0.0)	
2 quadrants, no. (%)	7 (6.7)	6 (28.6)	1 (1.2)	
3 quadrants, no. (%)	19 (18.3)	6 (28.6)	13 (15.7)	
4 quadrants, no. (%)	77 (74.0)	8 (38.1)	69 (83.1)	
Simplified RALE score, median (Q1-Q3), n=105	8.0 (6.0-8.0)	6.0 (4.0-8.0)	8.0 (7.0-8.0)	< 0.001
Severity scoring system				
SOFA score, median (Q1-Q3), n=79	4.0 (2.0-5.0)	2.0 (0.0-3.0)	4.0 (2.25-5.0)	0.002
APACHE II score, median (Q1-Q3), n=75	8.0 (3.0-12.0)	7.0 (2.0-8.75)	9.0 (4.0-13.0)	0.077
CURB-65 score, median (Q1-Q3), n=99	1.0 (1.0-2.0)	0.5 (0.0-1.0)	1.0 (1.0-2.0)	< 0.001

^a The comparison between patients who survived and those who died in the hospital.

<u>Abbreviations</u>: **APACHE II**, Acute Physiology and Chronic Health Evaluation II; **CRP**, C-reactive protein; **CURB-65**, Confusion, Urea >7 mmol/L, Respiratory Rate \geq 30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 mm Hg (Diastolic), and Age \geq 65 Years Criteria; **IL-6**, Interleukin 6; **INR**, international normalized ratio; **no.**, number of patients; **PaO**₂, partial pressure of oxygen in arterial blood; **PaO**₂/**FiO**₂, the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration; **pH**, the acidity of the blood; **Q**, quartile; **SD**, standard deviation; **SOFA**, Sequential Organ Failure Assessment; **SpO**₂, peripheral capillary oxygen saturation; **RALE**, Radiographic Assessment of Lung Edema; **WBC**, white blood cell.

21

400 Overall predictive performance of simplified RALE score and other severity scoring 401 systems

402 Unlike the PaO₂/FiO₂ ratio (AUROC: 0.306 [95% CI: 0.124-0.487]; cut-off value \geq 46.5%; sensitivity: 98.0%; specificity: 9.1%; PAUROC =0.045), serum IL-6 level (AUROC: 0.610 403 404 [95% CI: 0.459-0.761]; cut-off value \geq 15.8pg/mL; sensitivity: 84.1%; specificity: 42.9%; P_{AUROC} =0.128), and APACHE II score (AUROC: 0.645 [95% CI: 0.504-0.785]; cut-off 405 value ≥ 11.5 ; sensitivity: 33.9%; specificity: 93.8; P_{AUROC} =0.078) (S6 Table in S1 File), the 406 simplified RALE score (AUROC: 0.747 [95% CI: 0.617-0.877]; cut-off value ≥ 5.5 ; 407 sensitivity: 93.9%; specificity: 45.5%; $P_{AUROC} < 0.001$) demonstrated the good discriminatory 408 ability in predicting hospital mortality (Fig 1, S6 Table in S1 File). Additionally, both the 409 SOFA score (AUROC: 0.747 [95% CI: 0.604-0.890]; cut-off value ≥3.5; sensitivity: 62.5%; 410 specificity: 80.0%; $P_{AUROC} = 0.003$) and the CURB-65 score (AUROC: 0.776 [95% CI: 411 0.665-0.887]; cut-off value ≥ 0.5 ; sensitivity: 89.9%; specificity: 50.0%; P_{AUROC} = 0.001) also 412 exhibited the good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 File). 413 S6 Table (S1 File) summarizes the overall predictive performance of other risk factors for 414 hospital mortality in critically ill COVID-19 patients with the Delta variant. 415

Figure 1. Overall predictive performance of simplified RALE, SOFA, CURB-65, and 416 APACHE II scores for hospital mortality in critically ill COVID-19 patients with the Delta 417 variant: The area under the ROC curves of the simplified RALE (AUROC: 0.747 [95% CI: 418 0.617-0.877]; cut-off value \geq 5.5; sensitivity: 93.9%; specificity: 45.5%; P_{AUROC} <0.001), the 419 SOFA score (AUROC: 0.747 [95% CI: 0.604-0.890]; cut-off value ≥3.5; sensitivity: 62.5%; 420 421 specificity: 80.0%; P_{AUROC} = 0.003), CURB-65 scores (AUROC: 0.776 [95% CI: 0.665-0.887]; cut-off value ≥ 0.5 ; sensitivity: 89.9%; specificity: 50.0%; P_{AUROC} = 0.001), and 422 APACHE II score (AUROC: 0.645 [95% CI: 0.504-0.785]; cut-off value \geq 11.5; sensitivity: 423

424 33.9%; specificity: 93.8; $P_{AUROC} = 0.078$) for predicting hospital mortality in critically ill 425 COVID-19 patients with the Delta variant. (Abbreviations: APACHE II, Acute Physiology 426 and Chronic Health Evaluation II; AUROC, areas under the receiver operating characteristic 427 curve; CI, confidence interval; CURB-65, Confusion, Urea >7 mmol/L, Respiratory Rate 428 \geq 30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 mm Hg (Diastolic), Age \geq 65 429 Years; RALE, Radiographic Assessment of Lung Edema; SOFA, Sequential Organ Failure 430 Assessment).

431 S7 Table (S1 File) shows the differences between the AUROC curves among different test-432 pairwise, of which the AUROCs for predicting hospital mortality did not differ significantly 433 between the simplified RALE score and SOFA score (AUROC difference: 0.015; 95% CI: -434 0.117 to 0.148; Z-statistic: 0.23; p = 0.819) and the simplified RALE score and CURB-65 435 score (AUROC difference: 0.046; 95% CI: -0.110 to 0.203; Z-statistic: 0.58; p = 0.562). S6 436 Table (S1 File) also present the AUROC differences between other risk factors for hospital 437 mortality in critically ill COVID-19 patients with the Delta variant.

438 Spearman's correlation between simplified RALE score and severity of illness

We used the Spearman's rank correlation coefficient to examine the associations between simplified RALE score and various severity scoring systems upon admission (Table 3, S8 Table in S1 File). We observed a modest correlation between the simplified RALE score and the serum IL-6 level (Rs=0.226; p=0.032), SOFA score (Rs=0.344; p=0.002), APACHE II score (Rs=0.231; p=0.046), and CURB-65 score (Rs=0.235; p=0.019). Spearman's correlation between other severity scoring systems upon admission is present in S8 Table (S1 File).

446 Association of simplified RALE score with hospital mortality

447	In the univariable logistic regression analysis, the simplified RALE score \geq 5.5 (OR: 13.000;
448	95% CI: 3.786-44.637; p <0.001) was significantly associated with an increased risk of
449	hospital mortality (Table 4). In the multivariable logistic regression analysis, after accounting
450	for confounding variables such as age (≥ 60 years), male gender, CCI score (≥ 1.5), serum IL-6
451	levels upon admission (\geq 15.8 pg/mL), SOFA score (\geq 3.5), and CURB-65 score (\geq 0.5), the
452	simplified RALE score ≥5.5 (adjusted OR: 18.437; 95% CI: 3.215-105.741; p =0.001)
453	remained independently associated with an increased risk of hospital mortality (Table 4).
454	Table 4 also shows other factors that were related to hospital mortality.

		Simplified	Serum IL-6	SOFA	APACHE II	CURB-65	PaO ₂ /FiO ₂
		RALE					
Simplified	Rs value	1.000	0.226	0.344	0.231	0.235	-0.158
RALE	P value	NA	0.032	0.002	0.046	0.019	0.220
	N	105	90	79	75	99	62

467 **Table 3**. Spearman's correlation between the the simplified RALE Score and the severity scoring systems upon admission

<u>Abbreviations</u>: **APACHE II**, Acute Physiology and Chronic Health Evaluation II; **CURB-65**, Confusion, Urea >7 mmol/L, Respiratory Rate \geq 30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 mm Hg (Diastolic), and Age \geq 65 Years Criteria; **IL-6**, Interleukin 6; **N**, number of patients; **NA**, not available; **PaO₂/FiO₂**, the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration; **Rs**, correlation coefficients; **SOFA**, Sequential Organ Failure Assessment; **RALE**, Radiographic Assessment of Lung Edema.

468

469 Table 4. Factors associated with hospital mortality in critically ill COVID-19 patients with the Delta variant upon admission

Factors	Univ	Univariable logistic regression analyses				Multivariable logistic regression analysis			
	OR	95% (95% CI for OR		AOR	95% (95% CI for AOR		
		Lower	Upper	_		Lower	Upper	_	
Demographics									
Age ≥ 60 years	1.039	1.005	1.074	0.023	NA	NA	NA	NA	
Gender (male)	2.043	0.726	5.743	0.176	NA	NA	NA	NA	
Comorbidities									
CCI score $\geq 1.5^{a}$	1.401	1.027	1.915	0.033	NA	NA	NA	NA	
Initial chest imaging									

Simplified RALE score \geq	13.000	3.786	44.637	< 0.001	18.437	3.215	105.741	0.001
5.5ª								
Laboratory investigation								
The 1st-day serum IL-6	2.514	0.927	6.822	0.070	NA	NA	NA	NA
level \geq 15.8 pg/mL ^a								
Severity of illness								
SOFA Score $\geq 3.5^{a}$	6.667	1.707	26.042	0.006	NA	NA	NA	NA
CURB-65 Score $\ge 0.5^{a}$	8.875	2.835	27.786	< 0.001	15.124	3.004	76.148	0.001
Constant					0.062			0.008

^a The number represents the best cut-off value determined by analysing the receiver operator characteristic curve for each variable.

<u>Abbreviations</u>: AOR, adjusted odds ratio; APACHE II, Acute Physiology and Chronic Health Evaluation II; CCI, Charlson Comorbidity Index; CI, confidence interval; CURB-65, Confusion, Urea >7 mmol/L, Respiratory Rate \geq 30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 mm Hg (Diastolic), Age \geq 65 Years Criteria; IL-6, Interleukin 6; NA, not available; OR, odds ratio; SOFA, Sequential Organ Failure Assessment; RALE, the Radiographic Assessment of Lung Edema.

In the present study, we found that nearly four-fifths of critically ill COVID-19 patients with 477 478 the Delta variant died in the hospital (Tables 1 and 2). Upon admission, most patients exhibited bilateral lung opacities on their CXR, with the highest occurrence of opacity 479 480 distribution spanning three to four quadrants of the lungs (Table 2), a high median simplified RALE score (Table 2), and a low mean PaO₂/FiO₂ ratio (Table 2). In contrast to the 481 PaO₂/FiO₂ ratio, serum IL-6 level, and APACHE II score (S6 Table in S1 File), the simplified 482 RALE score exhibited a good discriminatory ability in predicting hospital mortality (Fig 1, 483 S6 Table in S1 File). Similarly, both the SOFA score and CURB-65 score also demonstrated 484 good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 File). Notably, 485 there were no differences between the AUROC curves of the simplified RALE score and 486 those of the SOFA and CURB-65 score (S7 Table in S1 File). Although the coefficients were 487 modest, the simplified RALE score correlated with the SOFA and CURB-65 scores (Table 488 489 3). Furthermore, the present study revealed a significant association between the simplified RALE score of ≥ 5.5 and an increased risk of hospital mortality (Table 4). Even after 490 adjusting for confounding factors such as age (≥ 60 years), male gender, CCI score (≥ 1.5), 491 serum IL-6 levels upon admission (\geq 15.8 pg/mL), SOFA score (\geq 3.5), and CURB-65 score 492 (≥ 0.5) , the simplified RALE score of ≥ 5.5 remained independently associated with an 493 increased risk of hospital mortality (Table 4). 494

In our study, the hospital mortality rate is higher than the rates reported in other Vietnamese studies conducted in Ho Chi Minh City (52.2%; 263/504)(15) and Binh Duong Province (64.2%; 97/151)(32), as well as an Indian study (54.6%; 306/560)(31). These disparities may arise from variations in the inclusion criteria across studies. For example, our study only included critically ill COVID-19 patients who had CXRs taken upon hospital admission. 500 Moreover, our hospital mortality rate greatly surpasses that reported in a Swedish study (38.2%; 190/498)(33). The variation observed may stem from differences in the patients, 501 pathogens, and clinical ability to care for critically ill patients between low- to middle-income 502 and high-income country settings.(34-37) Additionally, the study centre almost only admitted 503 critically ill patients with COVID-19 (92.4%, 85/92; S1 Table in S1 File) who encountered 504 difficulties accessing treatment at lower-level hospitals, with a low rate of intubation (16.7%, 505 16/96; S1 Table in S1 File) and mechanical ventilation (14.0%, 14/100; S1 Table in S1 File) 506 during transportation. Transferring critically ill patients with COVID-19 from a local to a 507 508 central hospital may result in the worsening of their critical condition. Patient transfers in Vietnam may occur without intubation, ventilation, PEEP, and other medical 509 interventions.(38-40) Although data on transfer conditions is limited, a prior survey 510 highlighted several risk factors associated with increased patient transfers and suboptimal 511 pre-hospital care quality.(41) Therefore, the cohort of the present study is likely to be 512 overestimated in the hospital mortality rate. 513

In the early COVID-19 pandemic, the requirement to transfer a patient with COVID-19 to an 514 ICU mainly depends on their SpO₂, in addition to concurrent comorbidities.(6) However, 515 there is a suggestion that this determination could also be made using imaging. Furthermore, 516 CXRs have also been proposed as a measure for predicting the severity of COVID-19 by 517 assessing the extent of lung involvement (7-9, 11, 12, 26), thereby offering insights into the 518 prognosis of the infection. Although data on simple CXR severity scoring systems for 519 COVID-19 patient mortality is scarce, a Pakistan retrospective study indicates that the initial 520 simplified RALE score (adjusted OR: 1.278; 95% CI: 1.010-1.617) is identified as an 521 independent predictor of hospital mortality.(11) Similarly, another Vietnamese retrospective 522 study also shows that the simplified RALE score (OR: 1.10; 95% CI: 1.04-1.18) is 523 significantly associated with a higher risk of hospital mortality.(12) These findings align with 524

the present study, which highlighted the good predictive ability of the simplified RALE score in assessing hospital mortality risk (Fig 1), particularly when the score reaches \geq 5.5 (Table 4). For pinpointing those most at risk of dying among critically ill COVID-19 patients, the simplified RALE score may be utilized effectively.

529 The present study unveiled that the PaO₂/FiO₂ ratio and serum IL-6 level exhibited a poor discriminatory ability in predicting hospital mortality (S6 Table in S1 File). The reliability of 530 these measures remains a topic of ongoing debate.(42-51) A Chinese retrospective study 531 demonstrated that the PaO₂/FiO₂ ratio (with an AUROC of 0.865 and a 95% CI of 0.748-532 0.941) had excellent discrimination in predicting hospital mortality in COVID-19 patients 533 requiring intensive care.(42) However, an Italian prospective study revealed a contrasting 534 result, with the PaO₂/FiO₂ ratio (AUROC: 0.688, 95% CI: 0.650-0.846) showing poor 535 discriminatory ability in predicting hospital mortality.(44) An earlier critique identified a 536 caution problem with the PaO₂/FiO₂ ratio: while PaO₂ accurately reflects a COVID-19 537 patient's oxygenation, its reliability diminishes when expressed as a PaO₂/FiO₂ ratio.(43) As 538 a result, inconsistent data may arise regarding the predictive value of this ratio.(42, 44) In 539 terms of serum IL-6 level, the Chinese study found it had an excellent discriminatory ability 540 to predict hospital mortality (AUROC: 0.900, 95% CI: 0.791-0.964).(42) However, a meta-541 analysis suggested that although serum IL-6 is a useful diagnostic marker for predicting 542 severe disease, it does not appear to be associated with COVID-19 mortality.(46) 543 Interestingly, a Belgian retrospective study observed significant differences in serum IL-6 544 levels between survivors and non-survivors over time, with the maximum serum IL-6 value 545 546 emerging as a predictor of ICU mortality in critically ill COVID-19 patients.(47) Thus, integrating serum IL-6 into the COVID-19 prognosis warrants further exploration. 547

The spectrum of COVID-19 in adults ranges from asymptomatic infection to mild respiratory 548 tract symptoms to severe pneumonia with ARDS and multi-organ dysfunction. For patients 549 with a working diagnosis of COVID-19 pneumonia, the crucial steps in management are 550 defining the severity of the illness and determining the most appropriate site of care. 551 Clinicians frequently use the CURB-65 severity score due to its straightforwardness.(25) The 552 present study found that the CURB-65 score exhibited good discrimination in predicting 553 hospital mortality (Fig 1, S6 Table in S1 File), consistent with the finding from a 554 comprehensive analysis of 22 predictive models applied to 411 hospitalized adults with 555 556 COVID-19, which also highlighted that the CURB-65 score demonstrated good discriminatory ability in predicting 30-day mortality (AUROC: 0.75, 95% CI: 0.7–0.8)(52). 557 Several predictive models have been suggested, but none stands out as significantly superior 558 or precisely predicts the deterioration or mortality in critically ill patients with COVID-559 19.(34, 35, 52-56) Although the APACHE IV score is the most up-to-date version, some 560 centres still use older versions, including the APACHE II score. The present study showed 561 that the APACHE II score had poor discrimination in predicting hospital mortality in 562 critically ill COVID-19 patients (S6 Table in S1 File), aligned with the finding of an earlier 563 published Belgian retrospective study, which also reported a poor discriminatory ability in 564 predicting hospital mortality using the APACHE II score (AUROC: 0.633).(56) These 565 findings are supported by previous studies, which revealed that the APACHE II score had a 566 good prognostic value in acutely ill or surgical patients (24, 57) but did not differentiate 567 between sterile and infected necrotizing pancreatitis and had a poor predictive value for the 568 severity of acute pancreatitis at 24 hours (58). However, the present study showed that the 569 570 SOFA score demonstrated good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 File). In a large American cohort of patients with COVID-19 who were without 571 mechanical ventilation within 24 hours of admission and those without a designation of do-572

not-resuscitate (DNR) status present at admission, the SOFA score (AUROC: 0.66, 95% CI:
0.65–0.67) exhibited a poor discriminatory ability in predicting hospital mortality.(54) This
variation might be because the illness severity of our patients was worse than those of the
large American cohort (mean SOFA score: 2.77 (SD: 1.91))(54). These findings are
supported by an Iranian prospective study, which reported that the mean of daily SOFA
scores during ICU admission (AUROC: 0.895) had excellent discrimination in predicting
hospital mortality(59).

As previously mentioned, the predictive value of the test results and predictive models we 580 discussed for assessing critically ill patients with COVID-19 remains uncertain, and the 581 optimal utilization of these diagnostic markers and models remains unknown. However, the 582 present study shows that the simplified RALE score, SOFA score, and CURB-65 score 583 demonstrated good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 584 File), with no differences between their AUROC curves (S7 Table in S1 File). Although the 585 586 coefficients were modest, the simplified RALE score correlated with the SOFA and CURB-65 scores (Table 3, S8 Table in S1 File). These findings align with previously published 587 studies, which report that the CXR scoring system is suggested as a tool to predict the 588 severity of COVID-19 by assessing lung involvement(7-9, 11, 12). Thus, to quantify the 589 severity of COVID-19 pneumonia, the simplified RALE score may also be utilized 590 effectively. 591

The present study has certain limitations. *Firstly*, it was conducted at a single centre in Ho Chi Minh City, Vietnam, focusing on a highly selected group of cases. The study site was urgently established in Ho Chi Minh City in response to the Delta variant epidemic, which posed significant challenges for medical providers dealing with a large influx of COVID-19 patients. Additionally, all COVID-19 patients were transferred from various hospitals within

the Ho Chi Minh City area, and the treatments they received before admission influenced 597 their disease severity upon enrolment. As a result, these elements hinder the seamless 598 integration of pre-hospital and hospital treatment procedures, as well as the collection of 599 clinical data for surveillance, quality enhancement, and research purposes. Additionally, they 600 introduce an implicit selection bias and incomplete patient inclusion in the study database, 601 which could potentially result in an overestimation of the mortality rate. Secondly, we 602 conducted the present study during the Delta variant epidemic in Vietnam; however, no 603 included patients with COVID-19 underwent genomic analysis to confirm infection with a 604 605 SARS-CoV-2 mutant virus strain. However, according to sequencing data at the time of the study period in Ho Chi Minh City, COVID-19 was almost entirely caused by one lineage of 606 the Delta variant (AY.57).(60) In that sense, we evaluated a relatively homogeneous patient 607 608 population in virologically. Finally, although the sample size was large enough, the confidence interval was wide ($\pm 8.02\%$), which might influence the normal distribution of the 609 collected sample. Further studies with larger sample sizes might be needed to consolidate the 610 conclusions. 611

612

613 CONCLUSIONS

This study investigated a highly selected cohort of critically ill COVID-19 patients with the Delta variant, a high simplified RALE score, and a high mortality rate presented to an Intensive Care Centre for the Treatment of Critically Ill Patients with COVID-19 in Ho Chi Minh City, Vietnam. Beyond its ability to quantify severity and predict hospital mortality, the simplified RALE score also emerged as an independent predictor of hospital mortality. For pinpointing those most at risk of progressing and dying among critically ill COVID-19 patients, the simplified RALE score can be utilized effectively. 621

622 Acknowledgements

We are grateful to the special task teams from the Bach Mai Hospital and Vietnam's Ministry 623 of Health and to all the healthcare heroes across the country who helped Ho Chi Minh City 624 during the third wave of the COVID-19 pandemic in Vietnam. We also appreciate the support 625 and statistical advice from the staff of the Faculty of Public Health at the Thai Binh 626 University of Medicine and Pharmacy. Finally, we thank Miss Truc-Cam Nguyen from 627 Stanford University, Stanford, California, the United States of America, and Miss Mai 628 Phuong Nguyen from the Hotchkiss School, Lakeville, Connecticut, the United States of 629 America, for their support of our manuscript. 630

631

632 **References**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
Patients with Pneumonia in China, 2019. The New England journal of medicine.
2020;382(8):727-33.

World Health Organization (WHO). Statement on the second meeting of the
International Health Regulations (2005) Emergency Committee regarding the outbreak of
novel coronavirus (2019-nCoV). Geneva, Switzerland: WHO; 2020 [updated January 30,
2020; cited 2024 February 25]. Available from: https://www.who.int/news-room/detail/3001-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).

World Health Organization (WHO). WHO Director-General's opening remarks at the 3. 642 media briefing on COVID-19 - 11 March 2020. Geneva, Switzerland: WHO; 2020 [updated 643 11, 2024 25]. 644 March 2020; cited February Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-645 media-briefing-on-covid-19---11-march-2020. 646

4. Number of COVID-19 cases reported to WHO (cumulative total) [Internet]. WHO.
2024 [cited February 22, 2024]. Available from: https://data.who.int/dashboards/covid19/cases.

5. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers.
International journal of infectious diseases : IJID : official publication of the International
Society for Infectious Diseases. 2020;95:304-7.

6. Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, et al.
Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783
Italian patients. La Radiologia medica. 2020;125(5):461-4.

Monaco CG, Zaottini F, Schiaffino S, Villa A, Della Pepa G, Carbonaro LA, et al.
Chest x-ray severity score in COVID-19 patients on emergency department admission: a twocentre study. European radiology experimental. 2020;4(1):68.

8. Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray
scoring system for quantifying and monitoring disease progression. La Radiologia medica.
2020;125(5):509-13.

Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al.
Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVIDRadiology. 2020;296(2):E72-E8.

Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, et al.
Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes
in ARDS. Thorax. 2018;73(9):840-6.

Kaleemi R, Hilal K, Arshad A, Martins RS, Nankani A, Tu H, et al. The association
of chest radiographic findings and severity scoring with clinical outcomes in patients with
COVID-19 presenting to the emergency department of a tertiary care hospital in Pakistan.
PloS one. 2021;16(1):e0244886.

Hoang SV, Nguyen KM, Huynh TM, Huynh KLA, Nguyen PH, Tran HPN. Chest Xray Severity Score as a Putative Predictor of Clinical Outcome in Hospitalized Patients: An
Experience From a Vietnamese COVID-19 Field Hospital. Cureus. 2022;14(3):e23323.

Takashima K, Wada K, Tra TT, Smith DR. A review of Vietnam's healthcare reform
through the Direction of Healthcare Activities (DOHA). Environmental health and preventive
medicine. 2017;22(1):74.

World Health Organization. COVID-19 Situation reports in Viet Nam Geneva,
Switzerland: The World Health Organization; 2021 [updated June 7, 2023; cited 2024
February 14]. Available from: https://www.who.int/vietnam/emergencies/coronavirusdisease-(covid-19)-in-viet-nam/covid-19-situation-reports-in-viet-nam/.

15. Do TV, Manabe T, Vu GV, Nong VM, Fujikura Y, Phan D, et al. Clinical
characteristics and mortality risk among critically ill patients with COVID-19 owing to the
B.1.617.2 (Delta) variant in Vietnam: A retrospective observational study. PloS one.
2023;18(1):e0279713.

16. World Health Organization (WHO). Public health surveillance for COVID-19:
interim guidance. Geneva, Switzerland: WHO; 2020 [updated July 22, 2022; cited 2024]

February 14]. Available from: https://www.who.int/publications/i/item/who-2019-nCoVsurveillanceguidance-2020.8/.

690 17. Vietnam Ministry of Health. Decision 4689/QĐ-BYT 2021 on the Guidance on
691 COVID-19 diagnosis and treatment. In: Department of Medical Service Administration,
692 editor. 7th ed. Hanoi, Vietnam: Ministry of Health,; 2021.

Patel A, Jernigan DB. Initial Public Health Response and Interim Clinical Guidance
for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4,
2020. MMWR Morbidity and mortality weekly report. 2020;69(5):140-6.

19. NIH COVID-19 Treatment Panel. Coronavirus Disease 2019 (COVID-19) Treatment 696 Guidelines Maryland, United States of America: National Institutes of Health; 2020 [updated 697 December 20, 2023; 2024 February 14]. Available from: 698 cited https://www.covid19treatmentguidelines.nih.gov/. 699

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation. Journal of
chronic diseases. 1987;40(5):373-83.

Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and
validating the Charlson comorbidity index and score for risk adjustment in hospital discharge
abstracts using data from 6 countries. American journal of epidemiology. 2011;173(6):67682.

Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, et al. Validity of
Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights
from the nationwide AMIS Plus registry 2002-2012. Heart (British Cardiac Society).
2014;100(4):288-94.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The
SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.
On behalf of the Working Group on Sepsis-Related Problems of the European Society of
Intensive Care Medicine. Intensive care medicine. 1996;22(7):707-10.

715 24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
716 disease classification system. Critical care medicine. 1985;13(10):818-29.

Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.
Defining community acquired pneumonia severity on presentation to hospital: an
international derivation and validation study. Thorax. 2003;58(5):377-82.

26. American College of Radiology (ACR). ACR Recommendations for the use of Chest
Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection Virginia,
United States: American College of Radiology; 2020 [updated March 22, 2020; cited 2024
March 11]. Available from: https://www.acr.org/Advocacy-and-Economics/ACR-PositionStatements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19Infection.

726 27. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al.
727 Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016
728 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American
729 Thoracic Society. Clinical infectious diseases : an official publication of the Infectious
730 Diseases Society of America. 2016;63(5):e61-e111.

731 28. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson
732 ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. Jama.
733 2012;307(23):2526-33.

Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, et al. The
Berlin definition of ARDS: an expanded rationale, justification, and supplementary material.
Intensive care medicine. 2012;38(10):1573-82.

30. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et
al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
Jama. 2016;315(8):801-10.

Mahendra M, Nuchin A, Kumar R, Shreedhar S, Mahesh PA. Predictors of mortality
in patients with severe COVID-19 pneumonia - a retrospective study. 2021;89(2):135-44.

32. Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Thi-Kim T, Nguyen-Quang T, TranNgoc-Anh T, Nguyen-Van-Hoai N, et al. Predictive Factors of Mortality in Patients with
Severe COVID-19 Treated in the Intensive Care Unit: A Single-Center Study in Vietnam.
Pulmonary therapy. 2023;9(3):377-94.

33. Didriksson I, Leffler M, Spångfors M, Lindberg S, Reepalu A, Nilsson A, et al.
Intensive care unit burden is associated with increased mortality in critically ill COVID-19
patients. Acta anaesthesiologica Scandinavica. 2023;67(3):329-38.

34. Do SN, Dao CX, Nguyen TA, Nguyen MH, Pham DT, Nguyen NT, et al. Sequential
Organ Failure Assessment (SOFA) Score for predicting mortality in patients with sepsis in
Vietnamese intensive care units: a multicentre, cross-sectional study. BMJ open.
2023;13(3):e064870.

35. Do SN, Luong CQ, Nguyen MH, Pham DT, Nguyen NT, Huynh DQ, et al. Predictive
validity of the quick Sequential Organ Failure Assessment (qSOFA) score for the mortality in
patients with sepsis in Vietnamese intensive care units. PloS one. 2022;17(10):e0275739.

36. Do SN, Luong CQ, Pham DT, Nguyen MH, Nguyen NT, Huynh DQ, et al. Factors
relating to mortality in septic patients in Vietnamese intensive care units from a subgroup
analysis of MOSAICS II study. Scientific reports. 2021;11(1):18924.

37. Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al.
Current challenges in the management of sepsis in ICUs in resource-poor settings and
suggestions for the future. Intensive care medicine. 2017;43(5):612-24.

762 38. Chinh LQ, Manabe T, Son DN, Chi NV, Fujikura Y, Binh NG, et al. Clinical
763 epidemiology and mortality on patients with acute respiratory distress syndrome (ARDS) in
764 Vietnam. PloS one. 2019;14(8):e0221114-e.

39. Do SN, Luong CQ, Pham DT, Nguyen CV, Ton TT, Pham TTN, et al. Survival after
out-of-hospital cardiac arrest, Viet Nam: multicentre prospective cohort study. Bulletin of the
World Health Organization. 2021;99(1):50-61.

40. Do SN, Luong CQ, Pham DT, Nguyen MH, Ton TT, Hoang QTA, et al. Survival after
traumatic out-of-hospital cardiac arrest in Vietnam: a multicenter prospective cohort study.
BMC emergency medicine. 2021;21(1):148.

41. Nielsen K, Mock C, Joshipura M, Rubiano AM, Zakariah A, Rivara F. Assessment of
the status of prehospital care in 13 low- and middle-income countries. Prehospital emergency
care : official journal of the National Association of EMS Physicians and the National
Association of State EMS Directors. 2012;16(3):381-9.

Gu Y, Wang D, Chen C, Lu W, Liu H, Lv T, et al. PaO(2)/FiO(2) and IL-6 are risk
factors of mortality for intensive care COVID-19 patients. Scientific reports.
2021;11(1):7334.

Tobin MJ, Jubran A, Laghi F. P (aO(2)) /F (IO(2)) ratio: the mismeasure of
oxygenation in COVID-19. The European respiratory journal. 2021;57(3).

44. Prediletto I, D'Antoni L, Carbonara P, Daniele F, Dongilli R, Flore R, et al.
Standardizing PaO2 for PaCO2 in P/F ratio predicts in-hospital mortality in acute respiratory
failure due to Covid-19: A pilot prospective study. European journal of internal medicine.
2021;92:48-54.

45. Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A,
Naranjo L, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19.
The Journal of allergy and clinical immunology. 2020;146(4):799-807.e9.

46. Liu X, Wang H, Shi S, Xiao J. Association between IL-6 and severe disease and
mortality in COVID-19 disease: a systematic review and meta-analysis. 2022;98(1165):8719.

47. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al.
Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. PloS one.
2021;15(12):e0244628.

48. Nikkhoo B, Mohammadi M, Hasani S, Sigari N, Borhani A, Ramezani C, et al.
Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a
prospective cohort study. BMC infectious diseases. 2023;23(1):311.

49. Hardavella G, Marinou I, Keramida E, Bellou E, Mavrea S, Georgakopoulou E, et al.
Can IL-6 serve as a reliable biomarker of clinical outcome in COVID19 pneumonia?
European Respiratory Journal. 2022;60(suppl 66):4140.

Jamoussi A, Messaoud L, Jarraya F, Rachdi E, Ben Mrad N, Yaalaoui S, et al.
Interleukin6 prediction of mortality in critically ill COVID19 patients: A prospective
observational cohort study. PloS one. 2023;18(3):e0279935.

Sivakorn C, Dechsanga J, Jamjumrus L, Boonnak K, Schultz MJ, Dondorp AM, et al.
High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as
Biomarkers in Critically Ill COVID-19 Patients. The American journal of tropical medicine
and hygiene. 2021;105(1):73-80.

Superation Section 2020;56(6):2003498.
Superation 22, Superation 22, Superational Content Section 24, Superational

810 53. Raschke RA, Agarwal S, Rangan P, Heise CW, Curry SC. Discriminant Accuracy of
811 the SOFA Score for Determining the Probable Mortality of Patients With COVID-19
812 Pneumonia Requiring Mechanical Ventilation. Jama. 2021;325(14):1469-70.

Keller MB, Wang J, Nason M, Warner S, Follmann D, Kadri SS. Preintubation
Sequential Organ Failure Assessment Score for Predicting COVID-19 Mortality: External
Validation Using Electronic Health Record From 86 U.S. Healthcare Systems to Appraise
Current Ventilator Triage Algorithms. Critical care medicine. 2022;50(7):1051-62.

55. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute Physiology and Chronic
Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus
Disease 2019. Critical care medicine. 2020;48(8):e657-e65.

Solution 56. Vandenbrande J, Verbrugge L, Bruckers L, Geebelen L, Geerts E, Callebaut I, et al.
Validation of the Acute Physiology and Chronic Health Evaluation (APACHE) II and IV
Score in COVID-19 Patients. Critical care research and practice. 2021;2021:5443083.

57. Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G, et al. Validation
of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive
care medicine. 2000;26(12):1779-85.

58. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. The American
journal of gastroenterology. 2006;101(10):2379-400.

828 59. Beigmohammadi MT, Amoozadeh L, Rezaei Motlagh F, Rahimi M, Maghsoudloo M,

Jafarnejad B, et al. Mortality Predictive Value of APACHE II and SOFA Scores in COVID-

19 Patients in the Intensive Care Unit. Canadian Respiratory Journal. 2022;2022:5129314.

60. Hoang TH, Vu GM, Tran MH, Tran TTH, Le QD, Tran KV, et al. Investigation of
target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of
COVID-19 in Vietnam. BMC infectious diseases. 2022;22(1):558.

834

- 835 Supporting information
- 836 S1 File. Supplementary Results




Figure 1